05:27 AM EDT, 08/07/2024 (MT Newswires) -- Ligand Pharmaceuticals ( LGND ) reported Q2 adjusted earnings late Tuesday of $1.40 per diluted share, down from $1.42 a year earlier.

Analysts polled by Capital IQ expected $1.06.

Revenue for the quarter ended June 30 was $41.5 million, up from $26.4 million a year earlier.

Three analysts surveyed by Capital IQ expected $34.3 million.

Reaffirming its guidance, the company said it expects full-year 2024 core adjusted earnings of $5 to $5.50 per diluted share.

The company expects 2024 revenue of $140 million to $157 million. Analysts polled by Capital IQ expect $151.4 million.

Price: 99.86, Change: +0.82, Percent Change: +0.83